ASND vs NVO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: NVO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASND and NVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASND and NVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. The business is built on TransCon, a prodrug technology that attaches a known parent drug to a carrier through a linker that releases the active molecule slowly and predictably, which lets Ascendis convert daily injections into weekly or monthly dosing. Three products are approved and marketed: SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide, developed as TransCon CNP), which received accelerated FDA approval with orphan exclusivity in May 2026 for pediatric achondroplasia. Trailing twelve month revenue is roughly ~EUR 866 million (about ~$1.0 billion), up roughly ~135 percent year over year, with gross margin near ~89 percent.

Full ASND guide

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ASND drivers: YORVIPATH is carrying the model; YUVIWEL opens a second large launch.
• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. For NVO, novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ASND if you believe its drivers more; NVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASND and NVO guides.

ASND. The trailing earnings multiple is the number most likely to mislead here, because reported net income of roughly ~EUR 496 million on a trailing basis is driven largely by the roughly ~EUR 679 million deferred tax asset recognized in the first quarter of 2026, not by operations. Price to sales near ~17x and forward price to earnings near ~38x are the cleaner framing, and both price in continued rapid growth from a base that has already tripled. Second quarter 2026 results, scheduled for August 13, 2026, are the next data point on whether the YORVIPATH ramp is holding and how YUVIWEL is converting enrollments into revenue.

NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

Headline figures (approximate, August 2026): ASND shows market cap ~$16.8 billion, revenue (ttm) ~EUR 866 million (about ~$1.0 billion), up ~135% year over year, most recent reported quarter (q1 2026) Revenue ~EUR 247 million; YORVIPATH ~EUR 197 million, SKYTROFA ~EUR 44 million, profitability Gross margin ~89%, operating margin ~-1.7%; Q1 non-IFRS net profit ~EUR 18 million; NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate).

ASND and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASND and NVO exposure against your real portfolio. It is not an investment adviser.